A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer
Type of Study: Clinical Trial
Sponsor / Support: LACOG
Primary Objectives: The primary objective is to evaluate if pembrolizumab improves Overall Response Rate in first-line setting associated with platinum-based chemotherapy.
Design: This is a phase II, multicenter, open-label, one-arm interventional trial.
Sample Size: 33 patients
Principal Investigator: Fernando Cotait Maluf
Countries LATAM: Brazil
Clinicaltrials.gov Identifier: NCT04224740
Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0221 – BRAVE
LACOG 0413 – Male Breast Cancer
LACOG 0419 – NEOSAMBA
LACOG 0615 – LATINABreast
LACOG 0715 – PALLAS
LACOG 0721 – Cherry Pick
LACOG 2118 – ALEXANDRA/IMpassion 030
Gastrointestinal
LACOG/GTG 0119 – NET
LACOG 0222 – GASPAR
LACOG 0421 – ACTION HIV
LACOG/GTG 1318 – Anal Registry
Genitourinary
LACOG 0121 – PET-PSMA
LACOG 0217 – IRONMAN
LACOG 0218 – Hercules
LACOG 0519 – PEACE III
LACOG 0522 – DORA
LACOG 0620 – ExBAT
LACOG 1120 – RENAL REGISTRY
LACOG 1818 – Prostate Cancer Registry
LACOG 2018 – Foundation Penile
Gynecological
LACOG 0223 / GOG-3073 – ROSELLA
LACOG 0521 – MADONNA
LACOG 0623 – eVOLVE-Cervical
LACOG 0820 – EVITA LATAM
LACOG 0920 – Senticol III
LACOG 1018 – PALBO in Ovarian Cancer
LACOG 1220 – CONOR
Head and Neck
LACOG 0319
LACOG 0720 – SMART-KEY
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0120 – EAP durva lung cancer
LACOG 0322 – EDUR-BRA
LACOG 0821
LACOG 1918
LACOG 2218 – PACIFIC BRAZIL
Radiation
LACOG 0122 – RADIANT
Closed studies
Breast
LACOG 0111 – MGH
LACOG 0312 – METASTATIC BC
LACOG 0414
LACOG 0801 – GLICO
Genitourinary
LACOG 0415 – APA in Prostate Cancer
LACOG 0515 – Testicular Registry
LACOG 1518 – Bladder Cancer Registry
Gynecological
LACOG 0215 – EVITA
Head and Neck
LACOG 0318 – Induction
Lung
LACOG 0211 – ALK
LACOG 0417 – CNS MTX
LACOG 0618
Parsimony
Neuro
LACOG 0619
Other studies
LACOG 0213 – AUGMENT
LACOG 0214 – FINEP